556 related articles for article (PubMed ID: 8613937)
1. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
2. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
Newton DJ; Wang RW; Lu AY
Drug Metab Dispos; 1995 Jan; 23(1):154-8. PubMed ID: 7720520
[TBL] [Abstract][Full Text] [Related]
5. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
6. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Paxton JW; Tingle MD; Kestell P
Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
9. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
10. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
Hesse LM; Venkatakrishnan K; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):133-40. PubMed ID: 11159802
[TBL] [Abstract][Full Text] [Related]
11. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Jones DR; Wrighton SA; Hall SD
Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
[TBL] [Abstract][Full Text] [Related]
12. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.
Pan LP; Wijnant P; De Vriendt C; Rosseel MT; Belpaire FM
Br J Clin Pharmacol; 1997 Dec; 44(6):557-64. PubMed ID: 9431831
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2002 May; 25(5):682-5. PubMed ID: 12033517
[TBL] [Abstract][Full Text] [Related]
15. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes.
Endo T; Ban M; Hirata K; Yamamoto A; Hara Y; Momose Y
Drug Metab Dispos; 2007 Mar; 35(3):476-83. PubMed ID: 17178767
[TBL] [Abstract][Full Text] [Related]
16. The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes.
Ueng YF; Jan WC; Lin LC; Chen TL; Guengerich FP; Chen CF
Drug Metab Dispos; 2002 Mar; 30(3):349-53. PubMed ID: 11854157
[TBL] [Abstract][Full Text] [Related]
17. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Br J Pharmacol; 2003 Apr; 138(8):1465-74. PubMed ID: 12721102
[TBL] [Abstract][Full Text] [Related]
18. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.
Meunier V; Bourrié M; Julian B; Marti E; Guillou F; Berger Y; Fabre G
Xenobiotica; 2000 Jun; 30(6):589-607. PubMed ID: 10923861
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
20. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
McKillop D; Wild MJ; Butters CJ; Simcock C
Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]